Document is current
Any future updates will be listed below
-
Authors
Feghali, James
Kim, Jennifer
Gami, Abhishek
Rapaport, Sarah
Caplan, Justin M.
McDougall, Cameron G.
Huang, Judy
Tamargo, Rafael J.
Jackson, Christopher M. https://orcid.org/0000-0002-5958-2004
- License Information
-
More Information
Article History
Received: 25 January 2021
Revised: 22 February 2021
Accepted: 15 March 2021
First Online: 10 April 2021
Declarations
:
: This study was approved by the Johns Hopkins Medicine Institutional Review Boards.
: Given the retrospective nature of the study and the absence of intervention as part of the study, patient consent was institutionally waived.
: No identifying information was included in the study; therefore, consent to publish was waived.
: C.M.J and R.J.T are inventors on a patent filed by Johns Hopkins for using PD-1 agonists to treat cerebral vasospasm and other monocyte-mediated inflammatory diseases as well as a diagnostic assay for cerebral vasospasm based on PD-1 + monocyte frequency in the peripheral blood. C.M.J is a co-founder of Egret Therapeutics and has equity interests in the company. All other authors declare no competing interests.
